Viral shedding and biodistribution of G207, a multimutated, conditionally replicating herpes simplex virus type 1, after intracerebral inoculation in Aotus

Molecular Therapy

Volumn 2, Issue 6, 2000, Pages 588-595

  Todo, Tomoki ^a,d   Feigenbaum, Frank ^a,e   Rabkin, Samuel D ^a,d   Lakeman, Fred ^b   Newsome, Joseph T ^a,f   Johnson, Paul A ^c   Mitchell, Erin ^c   Belliveau, Daniel ^c,g   Ostrove, Jeffrey M ^c   Martuza, Robert L ^a,d  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c NeuroVir Therapeutics Inc   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e Midwest Neurosurgery Associates   (United States)

^f UNIVERSITY OF PITTSBURGH   (United States)

^g UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

Brain; Gene therapy; Herpes simplex virus; Nonhuman primates; Safety study; Shedding; Toxicity; Viral therapy

Indexed keywords

AOTUS TRIVIRGATUS; HERPES; HUMAN HERPESVIRUS 1; PRIMATES; STRIGIFORMES;

PRIMER DNA; VIRUS ANTIBODY; VIRUS DNA;

ANIMAL; AOTUS; ARTICLE; BRAIN; FEMALE; GENE THERAPY; GENETICS; HERPES SIMPLEX VIRUS 1; IMMUNOLOGY; ISOLATION AND PURIFICATION; LACRIMAL FLUID; MALE; MUTATION; NUCLEOTIDE SEQUENCE; PHYSIOLOGY; POLYMERASE CHAIN REACTION; SALIVA; SECRETION; VAGINA; VIROLOGY; VIRUS REPLICATION; VIRUS SHEDDING;

ANIMALS; ANTIBODIES, VIRAL; AOTIDAE; BASE SEQUENCE; BRAIN; DNA PRIMERS; DNA, VIRAL; FEMALE; GENE THERAPY; HERPESVIRUS 1, HUMAN; MALE; MUTATION; POLYMERASE CHAIN REACTION; SALIVA; TEARS; VAGINA; VIRUS REPLICATION; VIRUS SHEDDING;

EID: 0034567125     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1006/mthe.2000.0200     Document Type: Article

References (44)

1. Davis, F. G., Freels, S., Grutsch, J., Barlas, S., and Brem, S. (1998). Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: An analysis based on surveillance, epidemiology, and end results (SEER) data, 1973-1991. J. Neurosurg. 88: 1-10.
2. Hunter, W., Rabkin, S., and Martuza, R. (1995). Brain tumor therapy using genetically engineered replication-competent virus. In Viral Vectors (M. G. Kaplitt and A. D. Loewy, Eds.), pp. 259-274, Academic Press. San Diego, CA.
3. Jacobs, A., Breakefield, X. O., and Fraefel, C. (1999). HSV-1-based vectors for gene therapy of neurological diseases and brain tumors: Part II. Vector systems and applications. Neoplasia 1: 402-416.
4. Martuza, R. L., Malick, A., Markert, J. M., Ruffner, K. L., and Coen, D. M. (1991). Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science 252: 854-856.
5. Markert, J. M., Malick, A., Coen, D. M., and Martuza, R. L. (1993). Reduction and elimination of encephalitis in an experimental glioma therapy model with attenuated herpes simplex mutants that retain susceptibility to acyclovir. Neurosurgery 32: 597-603.
6. Boviatsis, E. J., et al. (1994). Long-term survival of rats harboring brain neoplasms treated with ganciclovir and a herpes simplex virus vector that retains an intact thymidine kinase gene. Cancer Res. 54: 5745-5751.
7. Jia, W. W., McDermott, M., Goldie, J., Cynader, M., Tan, J., and Tufaro, F. (1994). Selective destruction of gliomas in immunocompetent rats by thymidine kinase-defective herpes simplex virus type 1. J. Natl. Cancer Inst. 86: 1209-1215.
8. Mineta, T., Rabkin, S. D., and Martuza, R. L. (1994). Treatment of malignant gliomas using ganciclovir-hypersensitive, ribonucleotide reductase-deficient herpes simplex viral mutant. Cancer Res. 54: 3963-3966.
9. Mineta, T., Rabkin, S. D., Yazaki, T., Hunter, W. D., and Martuza, R. L. (1995). Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat. Med. 1: 938-943.
10. Chambers, R., et al. (1995). Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in a seid mouse model of human malignant glioma. Proc. Natl. Acad. Sci. USA 92: 1411-1415.
11. Kesari, S., et al. (1995). Therapy of experimental human brain tumors using a neuroattenuated herpes simplex virus mutant. Lab. Invest. 73: 636-648.
12. Yazaki, T, Manz, H. J., Rabkin, S. D., and Martuza, R. L. (1995). Treatment of human malignant meningiomas by G207, a replication-competent multimutated herpes simplex virus 1. Cancer Res. 55: 4752-4756.
13. Pyles, R. B., Warnick, R. E., Chalk, C. L., Szanti, B. E., and Parysek, L. M. (1997). A novel multiply-mutated HSV-1 strain for the treatment of human brain tumors. Hum. Gene Ther. 8: 533-544.
14. Andreansky, S., et al. (1997). Evaluation of genetically engineered herpes simplex viruses as oncolytic agents for human malignant brain tumors. Cancer Res. 57: 1502-1509.
15. Andreansky, S., et al. (1998). Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukins. Gene Ther. 5: 121-130.
16. Todo, T., et al. (1999). Systemic antitumor immunity in experimental brain tumor therapy using a multimutated, replication-competent herpes simplex virus. Hum. Gene Ther. 10: 2741-2755.
17. Chou, J., Kern, E. R., Whitley, R. J., and Roizman, B. (1990). Mapping of herpes simplex virus-1 neurovirulence to gamma 34.5, a gene nonessential for growth in culture. Science 250: 1262-1266.
18. Goldstein, D. J., and Weller, S. K. (1988). Herpes simplex virus type 1-induced ribonucleotide reductase activity is dispensable for virus growth and DNA synthesis: isolation and characterization of an ICP6 lacZ insertion mutant. J. Virol. 62: 196-205.
19. Jacobson, J. G., et al. (1989). A herpes simplex virus ribonucleotide reductase deletion mutant is defective for productive acute and reactivatable latent infections of mice and for replication in mouse cells. Virology 173: 276-283.
20. Toda, M., Rabkin, S. D., and Martuza, R. L. (1998). Treatment of human breast cancer in a brain metastatic model by G207, a replication-competent multimutated herpes simplex virus 1. Hum. Gene Ther. 9: 2177-2185.
21. Toda, M., Rabkin, S. D., Kojima, H., and Martuza, R. L. (1999). Herpes simplex virus as an 'in situ vaccine' for the induction of specific antitumor immunity. Hum. Gene Ther. 10: 385-393.
22. Walker, J. R., McGeagh, K. G., Sundaresan, P., Jorgensen, T. J., Rabkin, S. D., and Martuza, R. L. (1999). Local and systemic therapy of human prostate adenocarcinoma with the conditionally replicating herpes simplex virus vector G207. Hum. Gene Ther. 10: 2237-2243.
23. Chahlavi, A., Todo, T., Martuza, R. L., and Rabkin, S. D. (1999). Replication-competent herpes simplex virus vector G207 and cisplatin combination therapy for head and neck squamous cell carcinoma. Neoplasia 1: 162-169.
24. Carew, J. F., Kooby, D. D., Halterman, M. W., Federoff, H. J., and Fong, Y. (1999). Selective infection and cytolysis of human head and neck squamous cell carcinoma with sparing of normal mucosa by a cytotoxic herpes simplex virus type 1 (G207). Hum. Gene Ther. 10: 1599-1606.
25. Kooby, D. A., et al. (1999). Oncolytic viral therapy for human colorectal cancer and liver metastases using a multi-mutated herpes simplex virus type-1 (G207). FASEB J. 13: 1325-1334.
26. Markert, J. M., et al. (2000). Conditionally-replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther. 7: 867-874.
27. Corey, L., and Spear, P. G. (1986). Infections with herpes simplex viruses. N. Engl. J. Med. 314: 749-757.
28. Sundaresan, P., Hunter, W. D., Martuza, R. L., and Rabkin, S. D. (2000). Attenuated, replication-competent herpes simplex virus type 1 mutant G207: safety evaluation in mice. J. Virol. 74: 3832-3841.
29. Katzin, D. S., Connor, J. D., Wilson, L. A., and Sexton, R. S. (1967). Experimental herpes simplex infection in the owl monkey. Proc. Soc. Exp. Biol. Med. 125: 391-398.
30. Hunter, W. D., et al. (1999). Attenuated, replication-competent, herpes simplex virus type 1 mutant G207: Safety evaluation of intracerebral injection in nonhuman primates. J. Virol. 73: 6319-6326.
31. Chalifoux, L. V., Bronson, P., Sehgal, P., Blake, B. J., and King, N. W. (1981). Nephritis and hemolytic anemia in owl monkeys (Aotus tivirgatus). Vet. Pathol. 18: 23-27.
32. Barahona, H., Melendez, L. V., Hunt, R. D., and Daniel, M. D. (1976). The owl monkey (Aotus tivirgatus) as an animal model for viral diseases and oncologic studies. Lab. Anim. Sci. 26: 1104-1112.
33. Meignier, B., Martin, B., Whitley, R. J., and Roizman, B. (1990). In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020. II. studies in immunocompetent and immunosuppressed owl monkeys (Aotus trivirgatus). J. Infect. Dis. 162: 313-321.
34. Melendez, L. V., España, C., Hunt, R. D., Daniel, M. D., and Garcia, F. G. (1969). Natural herpes simplex infection in the owl monkey (Aotus tivirgatus). Lab. Anim. Care 19: 38-45.
35. Kennedy, P. G., Adams, J. H., Graham, D. I., and Clements, G. B. (1988). A clinicopathological study of herpes simplex encephalitis. Neuropathol. Appl. Neurobiol. 14: 395-415.
36. Fathallah-Shaykh, H. M., Gao, W., Cho, M., and Herrera, M. A. (1998). Priming in the brain, an immunologically privileged organ, elicits anti-tumor immunity. Int. J. Cancer 75: 266-276.
37. Gordon, L. B., Knopf, P. M., and Cserr, H. F. (1992). Ovalbumin is more immunogenic when introduced into brain or cerebrospinal fluid than into extracerebral sites. J. Neuroimmunol. 40: 81-87.
38. Ohmoto, Y., Wood, M. J., Charlton, H. M., Kajiwara, K., Perry, V. H., and Wood, K. J. (1999). Variation in the immune response to adenoviral vectors in the brain: Influence of mouse strain, environmental conditions and priming. Gene Ther. 6: 471-481.
39. Harling-Berg, C., Knopf, P. M., Merriam, J., and Cserr, H. F. (1989). Role of cervical lymph nodes in the systemic humoral immune response to human serum albumin microinfused into rat cerebrospinal fluid. J. Neuroimmunol. 25: 185-193.
40. Harling-Berg, C. J., Park, T. J., and Knopf, P. M. (1999). Role of the cervical lymphatics in the Th2-type hierarchy of CNS immune regulation. J. Neuroimmunol. 101: 111-127.
41. McMenamin, M. M., Byrnes, A. P., Charlton, H. M., Coffin, R. S., Latchman, D. S., and Wood, M. J. (1998). A gamma34.5 mutant of herpes simplex 1 causes severe inflammation in the brain. Neuroscience 83: 1225-1237.
42. Lasner, T. M., Tal-Singer, R., Kesari, S., Lee, V. M., Trojanowski, J. Q., and Fraser, N. W. (1998). Toxicity and neuronal infection of a HSV-1 ICP34.5 mutant in nude mice. J. Neurovirol. 4: 100-105.
43. Kramm, C. M., et al. (1996). Long-term survival in a rodent model of disseminated brain tumors by combined intrathecal delivery of herpes vectors and ganciclovir treatment. Hum. Gene Ther. 7: 1989-1994.
44. Kramm, C. M., et al. (1997). Therapeutic efficiency and safety of a second-generation replication-competent HSV1 vector for brain tumor gene therapy. Hum. Gene Ther. 8: 2057-2068.